Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ViaDerma, Inc. (VDRM)
Marina del Rey, CA, US
ViaDerma, Inc., a specialty pharmaceutical enterprise based in the United States, focuses on both the development and commercialization of pharmaceutical products. It also licenses its proprietary technology to other companies within the pharmaceutical sector, addressing various therapeutic areas. The company's primary offering is Vitastem, a topical antibiotic containing tetracycline, effective for treating a broad spectrum of ailments such as cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Beyond its established products, ViaDerma is dedicated to expanding its pipeline, with ongoing development in fields including advanced topical antibiotics, antifungal treatments for toenails, diabetic amputation recovery, general acne, psoriasis, eczema, burn care, anti-aging and wrinkle-reducing formulations, medical cannabis applications, male pattern baldness, skin cancer, erectile dysfunction, and pain management. Established in 2007, the company operated as Décor Products International, Inc. until its renaming to ViaDerma, Inc. in May 2014. Its corporate operations are directed from Marina Del Rey, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +300.00% | +100.00% | -20.00% | -96.24% | -99.13% | -86.21% | -99.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+11.1% ★ Q3'24: 0.0% (vs Q3'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-100.0% Q3'24: -1,023.6% (vs Q3'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-57.0% Q3'24: -582.5% (vs Q3'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+13.4% ★ Q3'24: -196.1% (vs Q3'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+18.5% ★ Q3'24: -518.4% (vs Q3'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+71.5% Q3'24: +0.5% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.00× Q3'24: -1.58× (vs Q3'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baotang Zhao | Chief Sales Officer | 28.8K | male |
| Zhang Xie | Corporate Secretary and Director | 9.2K | male |
| Qing Hua Lin | Chief Financial Officer and Director | 4.5K | male |
| Andrew Berman | Medical Director and Member of Advisory Board | — | — |
| Christopher Otiko | Founder, Chief Executive Officer and President | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VDRM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
